(Q38174178)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Seto WK

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ching-Lung Lai

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

Man-Fung Yuen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology and Hepatology

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

428-434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372662%20AND%20SRC:MED&resulttype=core&format=json

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

3 March 2020

cites work

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

Clevudine myopathy in patients with chronic hepatitis B.

21 January 2018

1 reference

Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA.

21 January 2018

1 reference

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

21 January 2018

1 reference

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.

21 January 2018

1 reference

Telbivudine improves renal function in patients with chronic hepatitis B.

21 January 2018

1 reference

Exacerbation of peripheral neuropathy by lamivudine

21 January 2018

1 reference

Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage.

21 January 2018

1 reference

Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.

21 January 2018

1 reference

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy

21 January 2018

1 reference

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial

21 January 2018

1 reference

Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants

21 January 2018

1 reference

Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series

21 January 2018

1 reference

Lactic acidosis during telbivudine treatment for HBV: a case report and literature review

21 January 2018

1 reference

Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B.

21 January 2018

1 reference

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

21 January 2018

1 reference

Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation

21 January 2018

1 reference

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

21 January 2018

1 reference

LB80380: a promising new drug for the treatment of chronic hepatitis B

21 January 2018

1 reference